Revance Therapeutics reported $65.87M in Current Liabilities for its third fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Current Liabilities Change
Adamas Pharmaceuticals ADMS:US 23.84M 2.02M
Aerie Pharmaceuticals AERI:US $ 118.13M 10.04M
ALKERMES ALKS:US $ 452.98M 69.54M
Biodelivery Sciences International BDSI:US $ 77.66M 13.75M
Bristol Myers Squibb BMY:US $ 21460M 2469M
Cara Therapeutics CARA:US $ 15.53M 358K
Coherus Biosciences CHRS:US $ 320.35M 33.3M
Eli Lilly And LLY:US $ 13682M 1411.2M
Endo International Ordinary Shares ENDP:US $ 1554.27M 145.06M
Flexion Therapeutics FLXN:US $ 43.99M 4.06M
Gw Pharmaceuticals GWPH:US $ 160.25M 0.44M
Horizon Pharma HZNP:US $ 854.04M 1.23M
JAZZ PHA JAZZ:US $ 735.05M 145.54M
Neurocrine Biosciences NBIX:US $ 225.9M 13M
Pacira Pharmaceuticals PCRX:US $ 225.79M 2.9M
Procter & Gamble PG:US $ 36589M 3457M
Revance Therapeutics RVNC:US $ 65.87M 7.63M
Supernus Pharmaceuticals SUPN:US $ 234.71M 48.74M
Teva Pharmaceutical Industries TEVA:US $ 11825M 866M
Zogenix ZGNX:US $ 78.43M 9.09M